Loading
11 standard-of-care settings across 5 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers |
|---|---|
| Screening, prevention and diagnosis | 2 |
| Early / localised | 3 |
| Advanced, first line | 2 |
| Third line and beyond | 1 |
| Other settings | 3 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Prevention | Universal HBV vaccination; antiviral suppression of HBV; direct-acting antiviral cure of HCV; alcohol and metabolic risk reduction. | NCCN · Hepatobiliary Cancers | 90 | |
| All comers | Surveillance | Six-monthly ultrasound ± AFP in cirrhosis and high-risk HBV carriers; abbreviated MRI where ultrasound is inadequate. | AASLD 2023 Practice Guidance | 40 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Early | Resection, ablation, transplant. | NCCN Guidelines: Hepatocellular Carcinoma | 40 | |
| All comers | Very early / early (BCLC 0-A) | Ablation (RFA/microwave) for ≤3 cm; resection for preserved liver function; transplantation within Milan or downstaged criteria; radiation segmentectomy as an alternative. | NCCN · Category 1 for resection/ablation/transplant | 40 | |
| All comers | Adjuvant after resection/ablation | No approved adjuvant therapy; IMbrave050 benefit not sustained. Surveillance imaging every 3-6 months. | 53 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Advanced | Atezolizumab-bevacizumab, durvalumab-tremelimumab, or nivolumab-ipilimumab. | NCCN Guidelines: Hepatocellular Carcinoma | 98 | |
| All comers | Advanced (BCLC C), first line | Atezolizumab + bevacizumab (IMbrave150), STRIDE tremelimumab + durvalumab (HIMALAYA), or nivolumab + ipilimumab (CheckMate 9DW); lenvatinib or sorafenib if immunotherapy is contraindicated (transplant, active autoimmune disease). | NCCN · Category 1 (preferred) for all three IO reg…ESMO-MCBS · IMbrave150 grade 5 | 98 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Advanced, second line and beyond | After immunotherapy: lenvatinib, sorafenib, cabozantinib or regorafenib by extrapolation (no dedicated phase 3); ramucirumab if AFP ≥400 ng/mL; clinical trials. | NCCN · Category 2A after IO | 97 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Intermediate | TACE/TARE ± systemic therapy. | NCCN Guidelines: Hepatocellular Carcinoma | 96 | |
| All comers | Intermediate (BCLC B) | TACE (conventional or DEB-TACE) or TARE; systemic therapy for high tumour burden or TACE-refractory disease; TACE + durvalumab-bevacizumab or STRIDE + lenvatinib prolong PFS (OS unproven). | NCCN · TACE category 1; combinations not yet stand… | 78 | |
| All comers | Portal vein tumour thrombosis | Systemic immunotherapy; Y-90 radioembolisation where TACE is contraindicated; radiotherapy to the thrombus in selected patients. | 40 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.